Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Spironolactone on Metabolic Parameters and Arterial Compliance in Type 2 Diabetes
NCT01089309Phase 4Completed
- Sponsor
- Edith Wolfson Medical Center
- Start
- May 2004
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone in type 2 diabetes mellitus (T2DM), arterial stiffness, sponsored by Edith Wolfson Medical Center. Started May 2004; status: completed.
02
Drugs
spironolactone
03
Conditions
type 2 diabetes mellitus (T2DM)arterial stiffness
Beyond the preview
Go deeper on NCT01089309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01089309.